ACON Stock Overview
A healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Aclarion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.18 |
| 52 Week High | US$7.40 |
| 52 Week Low | US$0.16 |
| Beta | 0.40 |
| 11 Month Change | -22.05% |
| 3 Month Change | -25.46% |
| 1 Year Change | -95.86% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACON | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 5.3% | -5.2% | 0.3% |
| 1Y | -95.9% | 8.1% | 31.1% |
Return vs Industry: ACON underperformed the US Healthcare Services industry which returned 5.7% over the past year.
Return vs Market: ACON underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| ACON volatility | |
|---|---|
| ACON Average Weekly Movement | 12.8% |
| Healthcare Services Industry Average Movement | 9.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACON's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ACON's weekly volatility has decreased from 20% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 5 | Brent Ness | www.aclarion.com |
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. Fundamentals Summary
| ACON fundamental statistics | |
|---|---|
| Market cap | US$1.79m |
| Earnings (TTM) | -US$6.27m |
| Revenue (TTM) | US$49.29k |
36.8x
P/S Ratio-0.3x
P/E RatioIs ACON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACON income statement (TTM) | |
|---|---|
| Revenue | US$49.29k |
| Cost of Revenue | US$83.52k |
| Gross Profit | -US$34.23k |
| Other Expenses | US$6.23m |
| Earnings | -US$6.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | -69.45% |
| Net Profit Margin | -12,718.26% |
| Debt/Equity Ratio | 0% |
How did ACON perform over the long term?
See historical performance and comparison